A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not ...

Clinical staging ... thickness >4 mm is a powerful predictor of overall survival and may help guide the need for further adjuvant therapy (Gershenwald, Mansfield, Lee, & Ross, 2000). The Sunbelt ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study ...

While SLNB remains the standard for melanoma staging, many patients classified ... expression data with clinical factors age and tumor thickness, effectively identified two distinct risk groups ...